J. Scott Garland, Director at Enliven Therapeutics, Inc. (ELVN), sold 13,000 shares at $46.67 ($607K) on 2026-10-01, disclosed to the SEC on 2026-10-05.
Open-market sale of $607k ELVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.